Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of BAY 60-5521, a Potent Inhibitor of Cholesteryl Ester Transfer Protein

Trial Profile

Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of BAY 60-5521, a Potent Inhibitor of Cholesteryl Ester Transfer Protein

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2011

At a glance

  • Drugs BAY 605521 (Primary)
  • Indications Dyslipidaemias
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Aug 2011 Results published in the British Journal of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top